Anúncio
Anúncio

GLUE

GLUE logo

Monte Rosa Therapeutics, Inc. Common Stock

24.27
USD
Patrocinado
-1.04
-4.12%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

24.65

+0.39
+1.59%

Relatórios de Lucros GLUE

Rácio de surpresa positiva

GLUE separação 14 de 18 últimas estimativas.

78%

Próximo Relatório

Data do Próximo Relatório
18 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$15.82M
/
-$0.33
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+23.87%
/
--
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-73.92%
/
-243.48%

Monte Rosa Therapeutics, Inc. Common Stock earnings per share and revenue

On 06 de nov. de 2025, GLUE reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.38 USD, resulting in a 13.20% surprise. Revenue reached 12.77 milhão, compared to an expected 5.53 milhão, with a 130.95% difference. The market reacted with a +5.69% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analistas forecast an EPS of -0.33 USD, with revenue projected to reach 15.82 milhão USD, implying an aumentar of 0.00% EPS, and aumentar of 23.87% in Revenue from the last quarter.
FAQ
For Q3 2025, Monte Rosa Therapeutics, Inc. Common Stock reported EPS of -$0.33, beating estimates by 13.2%, and revenue of $12.77M, 130.95% above expectations.
The stock price moved up 5.69%, changed from $12.31 before the earnings release to $13.01 the day after.
The next earning report is scheduled for 18 de mar. de 2026.
Based on 9 analistas, Monte Rosa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of $15.82M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio